A randomized double-blind multicenter phase III study of fixed-dose single-administration pegfilgrastim versus daily filgrastim in patients receiving myelosuppressive chemotherapy

  1. Green, M.D.
  2. Koelbl, H.
  3. Baselga, J.
  4. Galid, A.
  5. Guillem, V.
  6. Gascon, P.
  7. Siena, S.
  8. Lalisang, R.I.
  9. Samonigg, H.
  10. Clemens, M.R.
  11. Zani, V.
  12. Liang, B.C.
  13. Renwick, J.
  14. Piccart, M.J.
  15. Yang, B.-B.
  16. Bashir, S.
  17. Hill, L.R.
  18. Breddy, J.
  19. Foote, M.A.
  20. Ackland, S.P.
  21. Andreesen, R.
  22. Bashford, J.
  23. Cascinu, S.
  24. Cocconi, G.
  25. Cocquyt, V.
  26. Coleman, R.E.
  27. Dunlop, D.
  28. Grothey, A.
  29. Holmes, F.A.
  30. Koczwara, B.
  31. Lind, M.J.
  32. Lluch, A.
  33. Marques, F.
  34. Miles, D.
  35. Richardson, G.E.
  36. Santoro, A.
  37. Schaafsma, M.R.
  38. Erakutsi egile guztiak +
Aldizkaria:
Annals of Oncology

ISSN: 0923-7534

Argitalpen urtea: 2003

Alea: 14

Zenbakia: 1

Orrialdeak: 29-35

Mota: Artikulua

DOI: 10.1093/ANNONC/MDG019 GOOGLE SCHOLAR lock_openSarbide irekia editor
Datuen iturria: Scopus